1
                                                      Filed by Merck & Co., Inc.
                           pursuant to Rule 425 under the Securities Act of 1933

                                     Subject company: Rosetta Inpharmatics, Inc.
                                                  Commission File No.: 000-30977
AGILENT
Press Contact:  Doug Forsyth
                (650) 485-5603

MERCK:
Press Contact:  Gwen Fisher                    Investor Contact:  Laura Jordan
                (908) 423-6154                                    (908) 423-5185


  AGILENT TECHNOLOGIES AND MERCK TO CONTINUE ALLIANCE FOR DEVELOPMENT OF GENE
                         EXPRESSION ANALYSIS SOLUTIONS

PALO ALTO, CALIF., AND WHITEHOUSE STATION, N.J., May 14, 2001 -- Agilent
Technologies, Inc. (NYSE: A) and Merck & Co., Inc. (NYSE: MRK) today affirm that
they plan to continue the strategic alliance begun in 1999 between Agilent and
Rosetta Inpharmatics, an informational genomics company based in Kirkland,
Wash., to develop technologies for gene expression research. Merck and Agilent
plan to continue the alliance upon completion of Merck's acquisition of Rosetta.
On May 11, Merck and Rosetta announced their definitive agreement under which
Merck will acquire Rosetta. The acquisition is subject to standard closing
conditions, and the two companies expect to complete the acquisition in the
third quarter of 2001.

         Along with Rosetta, Agilent is the exclusive distributor of the Rosetta
ResolverTM Expression Data Analysis System, a turnkey, enterprise-wide,
gene-expression bioinformatics solution for researchers in the pharmaceutical,
biotechnology and agriculture markets. The Agilent/Rosetta alliance uses inkjet
deposition technology. In addition, Rosetta is a major purchaser of Agilent DNA
microarrays.

         "We look forward to working with Merck on continuing development of the
Rosetta Resolver System, a leading platform for bioinformatics research," said
Bill Buffington, vice president and general manager of Agilent's Life Sciences
Business Unit. "Our customer base
                                    - more -

   2

continues to grow and Rosetta Resolver leads the industry in enterprise-scale
performance. We also look forward to working with Merck on the enhancement of
inkjet deposition technology and in servicing Merck as a customer of Agilent DNA
microarrays."

         "Merck is enthusiastic about the tools developed by Rosetta and our
interaction with Agilent," said Bennett Shapiro, M.D., executive vice president
of worldwide licensing and external research, Merck Research Laboratories. "Our
company will continue the activities related to the Rosetta Resolver business
and the key inkjet array technology. Moreover, we look forward to obtaining DNA
microarrays from Agilent and utilizing such technologies for drug discovery."

         "The collaboration between Rosetta and Agilent has produced what I
believe is one of the industry's most technologically advanced and robust gene
expression platforms," said Stephen Friend, M.D., Ph.D., president and chief
scientific officer of Rosetta Inpharmatics, Inc.

         Following Merck's acquisition of Rosetta, Agilent (along with Rosetta)
will continue to be the exclusive distributor of the Rosetta Resolver Expression
Data Analysis System. Rosetta will be run as a wholly owned Merck subsidiary and
will continue to operate under the name Rosetta Inpharmatics, Inc.

ABOUT AGILENT TECHNOLOGIES
         Agilent Technologies, Inc. is a diversified technology company with
approximately 47,000 employees serving customers in more than 120 countries.
Agilent is a global leader in designing and manufacturing test, measurement and
monitoring instruments, systems and solutions, and semiconductor and optical
components. In fiscal year 2000, Agilent had net revenue of $10.8 billion. The
company serves markets that include communications, electronics, life sciences
and healthcare. Information about Agilent Technologies can be found on the Web
at www.agilent.com.
                                    - more -


   3


ABOUT MERCK
         Merck & Co., Inc. is a leading research-driven pharmaceutical products
and services company. Merck discovers, develops, manufactures and markets a
broad range of innovative products to improve human and animal health, directly
and through its joint ventures. Merck-Medco manages pharmacy benefits for
employers, insurers and other plan sponsors, encouraging the appropriate use of
medicines and providing disease management programs. Through these complementary
capabilities, Merck works to improve quality of life and contain overall
health-care costs. For more information about Merck, visit www.merck.com.

         This press release contains "forward-looking statements" as that term
is defined in the Private Securities Litigation Reform Act of 1995. No
forward-looking statement can be guaranteed, and actual results may differ
materially from those projected. In particular, the following factors, among
others, could cause actual results to differ materially from those described in
the forward-looking statements: failure of the transaction to close due to the
failure to obtain regulatory or other approvals; failure of the Rosetta
stockholders to approve the transaction; the risk that the Rosetta business will
not be integrated successfully into Merck and unanticipated costs of such
integration; and failure to successfully manage relationships with customers,
suppliers and strategic partners during the pendency of and following the
transaction. We undertake no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events, or otherwise.
Forward-looking statements in this document should be evaluated together with
the many uncertainties that affect Merck's, Rosetta's and Agilent's businesses,
particularly those mentioned in the cautionary statements in Item 1 of each
company's Form 10-K for the year ended Dec. 31, 2000, and in each company's
periodic reports on Form 10-Q and Form 8-K (if any) which we incorporate by
reference.

         Rosetta and Merck will file a proxy statement/prospectus and other
relevant documents concerning the proposed merger transaction with the
Securities and Exchange Commission (SEC). Investors are urged to read the proxy
statement/prospectus when it becomes available and any other relevant documents
filed with the SEC because they will contain important information. You will be
able to obtain the documents and other filings by Rosetta and Merck with the SEC
at www.sec.gov. In addition, you may obtain the documents filed with the SEC by
Merck in connection with this transaction (including other documents
incorporated into these
                                    - more -

   4

filings) free of charge by requesting them in writing from Public Affairs
Information Resources Center, Merck & Co., Inc., One Merck Drive, Whitehouse
Station, NJ, 08889, and you may obtain documents filed with the SEC by Rosetta
in connection with this transaction free of charge by requesting them in writing
from Rosetta Investor Relations, 12040 115th Avenue NE, Kirkland, WA 98034.

         Rosetta and its directors and certain of its executive officers may be
deemed to be participants in the solicitation of proxies from Rosetta's
stockholders in connection with the merger. Information about the directors and
executive officers of Rosetta is set forth in Rosetta's proxy statement for its
2001 annual meeting of stockholders. This document is available free of charge
at the SEC web site at www.sec.gov and from Rosetta as described above.

                                      # # #